PTEN (Phosphatase and Tensin homolog deleted on chromosome 10) is one of the most frequently mutated tumor suppressors in human cancer. Its principal molecular function is the dephosphorylation of the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3), which positions PTEN as the key negative regulator of the PI3K-AKT-mTOR signaling axis. Beyond this canonical lipid-phosphatase activity, PTEN has been recognized as a dual-specificity phosphatase and as a scaffold-like regulator of the nucleus, the centrosome, and the immune response. This review focuses on the molecular architecture of PTEN, the structural basis of its lipid phosphatase activity, its regulation by phosphorylation, ubiquitylation, and oxidation, and its emerging phosphatase-independent nuclear functions. To support signaling-pathway and tumor-suppressor research, we provide multiplexed analysis services using protein array technology, meeting diverse needs in phosphoprotein profiling, kinase pathway activity mapping, and phosphatase regulatory network discovery.
Introduction
PTEN is a 403-residue, 47 kDa dual-specificity phosphatase that ranks among the most frequently inactivated genes in human cancer. Somatic loss-of-function mutations or deletions of PTEN are found in a broad spectrum of tumors, including glioblastoma, endometrial carcinoma, prostate cancer, breast cancer, and melanoma, and germline PTEN mutations underlie Cowden syndrome and related hamartoma-tumor predisposition disorders. From a molecular perspective, however, PTEN is more than a tumor suppressor. It is a central signaling node that ties lipid metabolism to cell growth, survival, and immune function, and the dissection of its molecular mechanism has become a paradigm for how a single protein can integrate catalytic, scaffolding, and regulatory functions to control cell behavior.
At the heart of PTEN biology is the PI3K-AKT signaling pathway, a central regulator of cell growth, survival, metabolism, and proliferation. Class I PI3 kinases phosphorylate the 3'-OH of the inositol ring of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which serves as a membrane-anchored second messenger that recruits and activates the serine/threonine kinase AKT and its downstream effectors, including mTOR, GSK3β, FOXO, and BAD. The opposing reaction—the dephosphorylation of PIP3 to regenerate PIP2—is carried out by PTEN, and it is this single enzymatic step that defines PTEN as the principal negative regulator of PI3K-AKT signaling. Loss of PTEN activity results in unrestrained accumulation of PIP3, constitutive AKT activation, and uncontrolled cell growth, which together constitute one of the most frequent molecular signatures in human cancer. The breadth of PTEN's biological roles extends well beyond the canonical PI3K-AKT pathway. PTEN has been recognized as a phosphatase for protein substrates, including the insulin receptor substrate-1 (IRS1), as a regulator of the tumor-suppressive APC-CDH1 complex in the nucleus, as a participant in chromosome integrity and DNA repair, and as a regulator of the immune response.
Figure 1. A schematic diagram depicting the most representative signaling of the PI3K/AKT pathway. (Source: Carnero A, et al. 2014)
PTEN and the PI3K-AKT-mTOR Signaling Axis
The canonical function of PTEN is the dephosphorylation of PIP3 at the 3'-position of the inositol ring, which directly opposes the activity of class I PI3K and thereby terminates PI3K-dependent signaling. The functional significance of this reaction was established by Myers and colleagues, who showed that a point mutation in the catalytic motif of PTEN (G129E) specifically inactivates lipid phosphatase activity while leaving protein phosphatase activity intact, and that this mutation abolishes the ability of PTEN to suppress cell growth and tumor formation in vivo. This experiment defined the lipid phosphatase activity of PTEN as the principal determinant of its tumor-suppressor function.
Stambolic and colleagues provided complementary evidence by showing that PTEN negatively regulates the phosphorylation and activity of AKT, and that loss of PTEN results in constitutive AKT activation that is resistant to upstream inhibition. Restoration of PTEN expression in PTEN-deficient cells reduces AKT phosphorylation, restores normal apoptosis sensitivity, and reverses the transformed phenotype. Together, these studies established the linear relationship PTEN → PIP3 → AKT as a central growth-control axis, and they explained why PTEN loss is sufficient to drive oncogenic transformation in a wide range of tissues.
Downstream of AKT, the PTEN-PI3K axis controls a network of effectors that includes mTORC1, GSK3β, FOXO transcription factors, and the pro-apoptotic protein BAD. Loss of PTEN therefore results in coordinated activation of growth, survival, and metabolic programs that together drive uncontrolled proliferation. This signaling cascade is also tightly linked to immune regulation, as AKT activation in T cells, B cells, and macrophages shapes the activation, differentiation, and effector function of these cells. PTEN has accordingly emerged as an important regulator of immune cell signaling, and PTEN-deficient mice display hyperactive PI3K-AKT signaling in lymphocytes that leads to defective immune tolerance and a propensity for autoimmunity and lymphoproliferative disease.
Post-Translational Regulation of PTEN
Given the centrality of PTEN to growth control, the activity of the protein is tightly regulated at multiple levels. Post-translational modifications play a central role in this regulation. Phosphorylation of the C-terminal tail of PTEN by casein kinase 2 (CK2) and other kinases stabilizes the protein but maintains it in a largely inactive, "closed" conformation; dephosphorylation of the tail by protein phosphatases releases autoinhibition and activates lipid phosphatase activity. This creates a feedback loop in which the balance between tail phosphorylation and dephosphorylation sets the steady-state activity of PTEN in cells.
Ubiquitylation is a second major mode of PTEN regulation. The E3 ubiquitin ligase NEDD4-1 has been identified as a key regulator of PTEN stability, catalyzing the K27-linked polyubiquitylation of PTEN that, while not directly targeting the protein for proteasomal degradation, modulates its activity, subcellular localization, and incorporation into protein complexes. Other E3 ligases, including WWP2, CHIP, and TRIM27, have been reported to ubiquitylate PTEN with distinct effects on its stability and activity, and deubiquitylating enzymes such as USP7 and USP13 have been shown to stabilize PTEN and to enhance its tumor-suppressor function. Oxidation of the catalytic cysteine of PTEN by reactive oxygen species provides a third layer of regulation, transiently inactivating the lipid phosphatase activity and thereby allowing localized, transient activation of PI3K-AKT signaling in response to oxidative stimuli.
Recent work has also highlighted the importance of non-covalent regulatory interactions. PTEN binds to a large set of partner proteins through its C-terminal PDZ-binding motif, including the PDZ domain-containing proteins MAGI1, MAGI2, and DLG1, which scaffold PTEN to specific membrane compartments and signaling complexes. Binding of PTEN to these scaffolds enhances its membrane recruitment and lipid phosphatase activity, and disruption of these interactions has been linked to reduced PTEN function in cancer. The long isoform PTEN-L, which contains an additional 173 residues at the N-terminus and includes a secretion signal, has been reported to be secreted from cells and to be taken up by neighboring cells, providing a non-cell-autonomous route by which PTEN activity can be spread within a tissue.
Figure 2. Schematic showing post-translational modifications important for PTEN nuclear import. (Source: Langdon CG. 2023)
Nuclear PTEN and Phosphatase-Independent Functions
A major conceptual shift in PTEN biology came with the recognition that PTEN has important functions in the nucleus that are, at least in part, independent of its lipid phosphatase activity. PTEN enters the nucleus through a process that involves diffusion and active transport, and its nuclear localization is regulated by a number of signals, including sumoylation and mono-ubiquitylation, which together determine the nucleocytoplasmic distribution of PTEN in cells. Reduced nuclear PTEN has been observed in many tumors, suggesting that nuclear PTEN has distinct tumor-suppressor functions that are not captured by cytoplasmic PIP3 hydrolysis.
Song and colleagues demonstrated in 2011 that nuclear PTEN interacts with the anaphase-promoting complex (APC) and its coactivator CDH1 to enhance the tumor-suppressive activity of the APC-CDH1 complex. This interaction is independent of PTEN's lipid phosphatase activity and instead depends on a phosphatase-independent scaffolding function of the protein. By promoting APC-CDH1-mediated degradation of cyclin B1 and other mitotic regulators, nuclear PTEN contributes to the maintenance of chromosomal stability and the prevention of aneuploidy, a hallmark of cancer.
Subsequent work has shown that nuclear PTEN also plays a role in the DNA damage response, the repair of double-strand breaks through homologous recombination, the regulation of centromere stability, and the control of rDNA transcription. These functions are mediated both by phosphatase-dependent and phosphatase-independent mechanisms, and they have collectively reframed PTEN from a "simple" lipid phosphatase to a multi-functional signaling and structural regulator. Importantly, the nuclear functions of PTEN are often lost in tumors that retain cytoplasmic PTEN expression, indicating that the loss of nuclear PTEN is a distinct and clinically important event in cancer progression.
Frequently Asked Questions (FAQs)
PTEN dephosphorylates the 3'-position of the inositol ring of phosphatidylinositol 3,4,5-trisphosphate (PIP3), regenerating phosphatidylinositol 4,5-bisphosphate (PIP2). This reaction directly opposes the activity of class I PI3 kinases and thereby terminates PI3K-dependent signaling to AKT and its downstream effectors. The lipid phosphatase activity of PTEN is essential for its tumor-suppressor function.
PTEN is regulated by phosphorylation of its C-terminal tail, which controls an autoinhibitory interaction between the tail and the phosphatase-C2 domain core; by K27- and K48-linked ubiquitylation, which modulates its stability and activity; by oxidation of the catalytic cysteine, which transiently inactivates the enzyme in response to oxidative stress; and by sumoylation, which controls its nuclear localization. PTEN is also regulated by interaction with PDZ domain-containing scaffold proteins and by the alternative translation of the long isoform PTEN-L.
PTEN is the principal negative regulator of AKT signaling. By dephosphorylating PIP3, PTEN prevents the membrane recruitment and activation of AKT. Loss of PTEN activity results in unrestrained accumulation of PIP3, constitutive AKT activation, and uncontrolled cell growth. The PTEN-PI3K-AKT axis is one of the most frequently deregulated growth-control pathways in human cancer.
Yes. PTEN has been recognized as a phosphatase for protein substrates, including the insulin receptor substrate-1 (IRS1); as a regulator of the tumor-suppressive APC-CDH1 complex in the nucleus; as a participant in chromosome integrity and DNA repair; and as a regulator of centromere stability and rDNA transcription. These functions are mediated by both phosphatase-dependent and phosphatase-independent mechanisms, and they collectively reframe PTEN as a multi-functional signaling and structural regulator.
Yes. Protein array platforms enable the parallel, quantitative measurement of dozens of phosphoproteins, cytokines, and signaling intermediates from a single small-volume sample. Combined with readouts of PI3K-AKT-mTOR pathway activity (phospho-AKT, phospho-GSK3β, phospho-S6K, phospho-4E-BP1), these platforms can provide a multidimensional picture of the PTEN-regulated signaling landscape in tumor-suppressor research and in studies of kinase pathway regulation.
References
- Carnero A, et al. The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol. 2014 Sep 23;4:252.
- Lee YR, et al. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562.
- Shi Y, et al. PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol. 2014 Jun;21(6):522-7.
- Song MS, et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell. 2011 Jan 21;144(2):187-99.
- Li X, et al. Post-Translational Modification of PTEN Protein: Quantity and Activity. Oncol Rev. 2024 Jul 31;18:1430237.
- Ho J, et al. PTEN Nuclear Functions. Cold Spring Harb Perspect Med. 2020 May 1;10(5):a036079.
- Langdon CG. Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers. Biomolecules. 2023 Jan 30;13(2):259.